The FDA cleared the PrecivityAD2 test for adults aged 40 years and older with signs of cognitive impairment being evaluated for Alzheimer disease.
New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell ...
Veru announces sabizabulin's potential as a treatment for daraxonrasib-resistant pancreatic cancer, supported by new ...
Welltica+ on MSN
The FDA just cleared a blood test for Alzheimer’s
A simple blood draw can now help doctors check for the plaques tied to Alzheimer’s.
The long-term study tracked 4,282 adults between the ages of 46 and 75 over a median observation period exceeding 12 years.
Compare the best lead scoring software for 2026, including HubSpot, ZoomInfo, Salesforce, Marketo, 6sense, and ActiveCampaign ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results